{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:41:19Z","timestamp":1761716479111},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s11255-010-9756-1","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T05:55:47Z","timestamp":1274162147000},"page":"865-873","source":"Crossref","is-referenced-by-count":11,"title":["Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience"],"prefix":"10.1007","volume":"43","author":[{"given":"Khalid","family":"Alsaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naila","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"9756_CR1","first-page":"125","volume":"2","author":"A Aldrees","year":"1991","unstructured":"Aldrees A, Paul TT, Abu-Aisha H et al (1991) Cost evaluation of hemodialysis in ministry of health hospitals, Saudi Arabia: a NKF study. Saudi Kidney Dis Transplant Bull 2:125\u2013133","journal-title":"Saudi Kidney Dis Transplant Bull"},{"key":"9756_CR2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002480-199801000-00019","volume":"44","author":"JI Tokars","year":"1998","unstructured":"Tokars JI, Miller ER, Alter MJ et al (1998) National surveillance of dialysis associated disease in the United States. ASAIO J 44:98\u2013107","journal-title":"ASAIO J"},{"key":"9756_CR3","unstructured":"Saudi Center for Organ Transplantation Annual Report (2006) www.scot.org.sa"},{"key":"9756_CR4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1542-4758.2007.00192.x","volume":"11","author":"A Karkar","year":"2007","unstructured":"Karkar A (2007) Hepatitis C in dialysis units: The Saudi experience. Hemodialysis Int 11:354\u2013367","journal-title":"Hemodialysis Int"},{"key":"9756_CR5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ki.1997.139","volume":"51","author":"BJG Pereira","year":"1997","unstructured":"Pereira BJG, Levey AS (1997) Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51:981\u2013989","journal-title":"Kidney Int"},{"key":"9756_CR6","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1128\/JCM.36.10.3066-3069.1998","volume":"36","author":"H Norder","year":"1998","unstructured":"Norder H, Bergstrom A, Uhnoo I et al (1998) Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. J Clin Microbiol 36:3066\u20133069","journal-title":"J Clin Microbiol"},{"key":"9756_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0272-6386(95)90617-7","volume":"25","author":"D Roth","year":"1995","unstructured":"Roth D (1995) Hepatitis C virus: the nephrologist\u2019s view. Am J Kidney Dis 25:3\u201316","journal-title":"Am J Kidney Dis"},{"key":"9756_CR8","first-page":"1011","volume":"41","author":"B Afsar","year":"2009","unstructured":"Afsar B, Elsurer R, Sezer S et al (2009) Quality of life in hemodialysis patients: hepatitis C virus infection makes sense Int Urol Nephrol 41:1011\u20131019","journal-title":"Quality of life in hemodialysis patients: hepatitis C virus infection makes sense Int Urol Nephrol"},{"key":"9756_CR9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","volume":"65","author":"C Legendre","year":"1998","unstructured":"Legendre C, Garrigue V, Le Bihan C et al (1998) Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 65:667\u2013670","journal-title":"Transplantation"},{"key":"9756_CR10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","volume":"5","author":"RG Knodell","year":"1981","unstructured":"Knodell RG, Ishak KG, Black WC et al (1981) Formulation \u2018and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 5:431\u2013435","journal-title":"Hepatology"},{"key":"9756_CR11","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.transproceed.2004.07.025","volume":"36","author":"DH Mousa","year":"2004","unstructured":"Mousa DH, Abdalla AH, Al-Shoail G et al (2004) Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Tranplant Proc 36:1831\u20131834","journal-title":"Tranplant Proc"},{"key":"9756_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jmv.1890350303","volume":"35","author":"EA Ayoola","year":"1991","unstructured":"Ayoola EA, Huraib S, Arif M et al (1991) Prevalence and significance of antibodies to hepatitis C virus among Saudi hemodialysis patients. J Med Virol 35:155\u2013159","journal-title":"J Med Virol"},{"key":"9756_CR13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/ndt\/9.8.1072","volume":"9","author":"MM Hussein","year":"1994","unstructured":"Hussein MM, Mooij JM, Roujouleh H et al (1994) Observations in a Saudi-Arabian dialysis population over a 13-year period. Nephrol Dial Transplant 9:1072\u20131076","journal-title":"Nephrol Dial Transplant"},{"key":"9756_CR14","first-page":"183","volume":"17","author":"A Karkar","year":"2006","unstructured":"Karkar A, Abdulrahman MR, Ghacha R et al (2006) Prevention of viral hepatitis in hemodialysis units: the value of isolation. Saudi J Kidney Dis Transplant 17:183\u2013188","journal-title":"Saudi J Kidney Dis Transplant"},{"key":"9756_CR15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/16.8.1669","volume":"16","author":"M Espinosa","year":"2001","unstructured":"Espinosa M, Martin-Malo A, Alvarez de Lara MA et al (2001) Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16:1669\u20131674","journal-title":"Nephrol Dial Transplant"},{"key":"9756_CR16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-6143.2003.00057.x","volume":"3","author":"JM Cruzado","year":"2003","unstructured":"Cruzado JM, Casanovas-Taltavull T, Torras J et al (2003) Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3:357\u2013360","journal-title":"Am J Transplant"},{"key":"9756_CR17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","volume":"78","author":"A Bruchfeld","year":"2004","unstructured":"Bruchfeld A, Wilczek H, Elinder CG (2004) Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78:745\u2013750","journal-title":"Transplantation"},{"key":"9756_CR18","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","volume":"14","author":"N Kamar","year":"2003","unstructured":"Kamar N, Toupance O, Buchler M et al (2003) Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14:2092\u20132098","journal-title":"J Am Soc Nephrol"},{"key":"9756_CR19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0272-6386(03)00828-X","volume":"42","author":"CM Meyers","year":"2003","unstructured":"Meyers CM, Seeff LB, Stehman-Breen CO et al (2003) Hepatitis C and renal disease: un update. Am J Kidney Dis 42:631\u2013657","journal-title":"Am J Kidney Dis"},{"key":"9756_CR20","first-page":"326","volume":"34","author":"MW Lamb","year":"2001","unstructured":"Lamb MW, Marks IM, Modi MW MW et al (2001) Peg interferon alfa-2a (40 kD) (Pegasys) can be administered safely in patients with end-stage renal disease (abstract). Hepatology 34:326","journal-title":"Hepatology"},{"key":"9756_CR21","first-page":"99","volume":"13","author":"I Sporea","year":"2004","unstructured":"Sporea I, Sirli R, Golea O et al (2004) Peg-interferon alfa-2a (40 kD) in patients on chronic haemodialysis with chronic hepatitis C. Preliminary results. Rom J Gastroenterol 13:99\u2013102","journal-title":"Rom J Gastroenterol"},{"key":"9756_CR22","doi-asserted-by":"crossref","unstructured":"Teta D, Landtwing L, \u00dcscher B, Gonvers J-J et al. (2005) Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 20:991\u2013993","DOI":"10.1093\/ndt\/gfh747"},{"key":"9756_CR23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1440-1746.2005.04008.x","volume":"21","author":"OF Kokoglu","year":"2006","unstructured":"Kokoglu OF, Uc\u00b8mak H, Hosoglu S et al (2006) Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21:575\u2013580","journal-title":"J Gastroenterol Hepatol"},{"key":"9756_CR24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1053\/jhep.2000.17914","volume":"32","author":"P Martin","year":"2000","unstructured":"Martin P, Mitra S, Farrington K et al (2000) Pegylated (40ku) Interferon alpha 2a (Pegasys) is unaffected by renal impairment (Abstract). Hepatology 32:842","journal-title":"Hepatology"},{"key":"9756_CR25","first-page":"293","volume":"16","author":"ASB Al-Harbi","year":"2005","unstructured":"Al-Harbi ASB, Malik GH, Subaity Y et al (2005) Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transplant. 16:293\u2013297","journal-title":"Saudi J Kidney Dis Transplant."},{"key":"9756_CR26","doi-asserted-by":"crossref","unstructured":"Sporea I, Popescu A, Sirli R et al. (2006) Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis treatment. J Gastroenterol 14(26):4191\u20134194","DOI":"10.3748\/wjg.v12.i26.4191"},{"key":"9756_CR27","first-page":"37","volume":"20","author":"G Barril","year":"2004","unstructured":"Barril G, Quiroga JA, Sanz P, Rodriguez-Salvanes F et al (2004) Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.Aliment. Pharmacol. Ther 20:37\u201344","journal-title":"Ther"},{"key":"9756_CR28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.gastro.2005.11.011","volume":"130","author":"JL Dienstag","year":"2006","unstructured":"Dienstag JL, McHutchison JG (2006) American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 130:225\u2013230","journal-title":"Gastroenterology"},{"key":"9756_CR29","unstructured":"Covic A, Maftei ID, Mardare NG et al. (2006) Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 19(6):794\u2013801"},{"key":"9756_CR30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2893.2005.00680.x","volume":"13","author":"A Bruchfeld","year":"2006","unstructured":"Bruchfeld A, Lindahl K, Reichard O et al (2006) Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13:316\u2013321","journal-title":"J Viral Hepat"},{"key":"9756_CR31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","volume":"46","author":"M Rendina","year":"2007","unstructured":"Rendina M, Schena A, Castellaneta NM et al (2007) The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kD) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46:768\u2013774","journal-title":"J Hepatol"},{"key":"9756_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2893.2001.00300.x","volume":"8","author":"A Bruchfeld","year":"2001","unstructured":"Bruchfeld A, Stahle L, Andersson J et al (2001) Ribavirin treatment in dialysis patients with chronic hepatitis C infection: a pilot study. J Viral Hepatitis 8:287\u2013292","journal-title":"J Viral Hepatitis"},{"key":"9756_CR33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ndt\/gfi231","volume":"21","author":"MW Russo","year":"2006","unstructured":"Russo MW, Ghalib R, Sigal S et al (2006) Randomized trial of pegylated interferon a-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21:437\u2013443","journal-title":"Nephrol Dial Transplant"},{"key":"9756_CR34","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/ndt\/gfl072","volume":"21","author":"A Bruchfeld","year":"2006","unstructured":"Bruchfeld A, Lindahl K, Reichard O et al (2006) Pegylated interferon and ribavirin in hemodialysis patients. Nephrol Dial Transplant 21:1444\u20131445","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"9756_CR35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11255-006-9092-7","volume":"41","author":"AA Sabry","year":"2009","unstructured":"Sabry AA, El-Dahshan KF, Mahmoud KM, El-Husseini A (2009) Effect of HCV infection on hematocrit and hemoglobin level in Egyptian hemodialysis patients. Int Urol Nephrol 41(1):189\u2013193","journal-title":"Int Urol Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-010-9756-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-010-9756-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-010-9756-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T20:04:11Z","timestamp":1591301051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-010-9756-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["9756"],"URL":"https:\/\/doi.org\/10.1007\/s11255-010-9756-1","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]}}}